<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-OHSOE51T</identifier><date>2016</date><creator>Battelino, Tadej</creator><creator>Dolžan, Vita</creator><creator>Grošelj, Urh</creator><creator>Hovnik, Tinka</creator><creator>Trebušak Podkrajšek, Katarina</creator><creator>Žerjav-Tanšek, Mojca</creator><relation>documents/doc/O/URN_NBN_SI_doc-OHSOE51T_001.pdf</relation><relation>documents/doc/O/URN_NBN_SI_doc-OHSOE51T_001.txt</relation><format format_type="issue">1</format><format format_type="volume">63</format><format format_type="type">article</format><format format_type="extent">str. 33-37</format><identifier identifier_type="ISSN">1318-0207</identifier><identifier identifier_type="COBISSID">32544473</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-OHSOE51T</identifier><language>eng</language><publisher>Slovensko kemijsko društvo</publisher><source>Acta chimica slovenica</source><rights>BY</rights><subject language_type_id="eng">congenital adrenal hyperplasia</subject><subject language_type_id="slv">CYP21A2</subject><subject language_type_id="slv">CYP2C19</subject><subject language_type_id="slv">prirojena nadledvična hiperplazija</subject><title>Clinical role of CYP2C19 polymorphisms in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency</title></Record>